Group 1 - The core viewpoint of the news is that MicroPort Robotics is set to hold a board meeting on March 26 to consider and approve the annual performance for the year ending December 31, 2025, with expectations of significant revenue growth and reduced net losses [1] - The company anticipates a revenue increase of approximately 110% to 120% year-on-year for the fiscal year ending December 31, 2025, with adjusted net losses not exceeding 240 million yuan, representing a reduction of over 50% compared to the previous year [1] - The substantial revenue growth is primarily attributed to breakthroughs in the commercialization of its core product, the TiMAY laparoscopic surgical robot, with rapid sales growth, particularly in overseas markets, where over 100 new orders were signed, resulting in overseas sales revenue exceeding five times that of the previous year [1] Group 2 - As of the latest trading data, MicroPort Robotics-B (02252) saw a pre-earnings increase of over 3%, with a current price of 25.06 HKD and a trading volume of 206 million HKD [2] - The stock has shown a percentage increase of 2.22% for the day, with a notable rise of 3.64% at the time of reporting [2]

Core Viewpoint - MicroPort Scientific Corporation (微创机器人-B) reported significant revenue growth and reduced losses for the fiscal year ending December 31, 2025, indicating strong market performance and expansion potential in the surgical robotics sector [2] Financial Performance - The company achieved a revenue of 551 million RMB, representing a year-on-year increase of 114.2% [2] - The loss attributable to equity shareholders narrowed to 250 million RMB, a reduction of 61.1% compared to the previous year [2] - Basic loss per share was reported at 0.24 RMB [2] Product and Market Development - The revenue growth was primarily driven by the commercialization of the core product, the TiMeye surgical robot, which has seen breakthrough progress [2] - Sales growth was particularly strong in overseas markets, with over 100 new orders signed in international markets throughout the year [2] - Overseas market sales revenue increased to more than five times that of the previous year, significantly outpacing the industry average growth rate, showcasing robust global expansion momentum [2]

Group 1 - The core viewpoint of the news is that MicroPort Robotics reported significant revenue growth and a reduction in losses for the fiscal year 2025, driven by the successful commercialization of its core product, the TiMeye surgical robot [1] - The company's revenue reached 551 million RMB, representing a year-on-year increase of 114.2% [1] - The loss attributable to equity shareholders narrowed to 250 million RMB, a decrease of 61.1% compared to the previous year [1] Group 2 - The revenue growth is primarily attributed to breakthroughs in the commercialization of the TiMeye surgical robot, with rapid sales growth, particularly in overseas markets [1] - The company signed over 100 new orders in overseas markets during the year, with overseas sales revenue exceeding five times that of the previous year, significantly outpacing the industry average growth rate [1] - This performance indicates strong global expansion momentum for the company [1]

近日，微创机器人发布截至2025年12月31日止年度业绩公告。公司录得收入5.51亿元，同比增长 114.2%。毛利为2.67亿元，同比增长209.2%。在税前亏损方面，公司的亏损为2.54亿元，较去年减少 60.7%。年内亏损也为2.54亿元，同比减少60.7%。经过调整的净亏损为1.65亿元，同比减少65.8%。每 股亏损为0.24元，较上年的0.66元减少63.6%。 近日，微创机器人发布截至2025年12月31日止年度业绩公告。公司录得收入5.51亿元，同比增长 114.2%。毛利为2.67亿元，同比增长209.2%。在税前亏损方面，公司的亏损为2.54亿元，较去年减少 60.7%。年内亏损也为2.54亿元，同比减少60.7%。经过调整的净亏损为1.65亿元，同比减少65.8%。每 股亏损为0.24元，较上年的0.66元减少63.6%。 公司业绩大幅增长的主要原因是核心产品图迈 腔镜手术机器人商业化取得突破性进展，尤其是在海外 市场的销售增长显著，全年新签海外市场订单逾百台，海外市场销售收入为去年的五倍以上，显示出强 劲的全球扩张动能。管理层提到，得益于收入增长、战略聚焦及降本增效措施的成功落实，自由 ...

微创机器人-B(02252)涨超8%，截至发稿，涨8.02%，报27.2港元，成交额9141.37万港元。 消息面上，微创机器人发布2025年度业绩，收入5.51亿元(人民币，下同)，同比增长114.2%；公司权益 股东应占亏损2.5亿元，同比收窄61.1%。公司指，期内收入同比增长主要归因于核心产品图迈®腔镜手 术机器人商业化取得突破性进展，销售增长迅猛，尤其是图迈海外市场拓展成效显著，全年新签海外市 场订单逾百台，全年海外市场销售收入为去年的五倍以上，增速远超行业平均水准，展现出强劲的全球 扩张动能。 ...

Core Viewpoint - MicroPort Scientific Corporation (02252) has shown significant growth in its 2025 fiscal year, with a revenue increase of 114.2% year-on-year, primarily driven by the commercialization of its core product, the TiMAY® laparoscopic surgical robot [5]. Financial Performance - The company's revenue reached 5.51 billion RMB, reflecting a substantial increase compared to the previous year [5]. - The loss attributable to equity shareholders was 250 million RMB, which represents a 61.1% reduction year-on-year [5]. Product and Market Expansion - The revenue growth is largely attributed to breakthroughs in the commercialization of the TiMAY® laparoscopic surgical robot, with rapid sales growth noted [5]. - The company has made significant strides in expanding its overseas market, signing over 100 new orders in international markets throughout the year [5]. - Sales revenue from overseas markets increased to more than five times that of the previous year, indicating a growth rate that far exceeds the industry average, showcasing strong global expansion momentum [5].

Core Viewpoint - Micron Robotics-B (02252.HK) reported significant revenue growth and reduced net loss for the fiscal year ending December 31, 2025, indicating strong operational improvements and market expansion [1] Financial Performance - The company recorded revenue of RMB 551 million, representing a year-on-year increase of 114.2% [1] - The net loss for the year was RMB 254 million, a reduction of 60.7% compared to the previous year [1] - Basic loss per share was RMB 0.24 [1] Operational Highlights - The substantial revenue increase was primarily driven by breakthroughs in the commercialization of the core product, the Tumai® laparoscopic surgical robot [1] - Sales growth was particularly strong in overseas markets, with over 100 new orders signed in these regions [1] - Overseas market sales revenue was more than five times that of the previous year, significantly outpacing industry averages and demonstrating robust global expansion momentum [1]

Core Viewpoint - MicroPort Robotics-B (02252) reported significant revenue growth and a reduction in losses for the fiscal year ending December 31, 2025, indicating strong performance driven by its core product, the TiMAY surgical robot [1] Financial Performance - Revenue reached 551 million RMB, representing a year-on-year increase of 114.2% [1] - The loss attributable to equity shareholders narrowed to 250 million RMB, a reduction of 61.1% compared to the previous year [1] - Basic loss per share was 0.24 RMB [1] Product and Market Expansion - The revenue growth was primarily due to breakthroughs in the commercialization of the TiMAY surgical robot [1] - Sales growth was particularly strong in overseas markets, with over 100 new orders signed in these regions during the year [1] - Overseas market sales revenue increased to more than five times that of the previous year, significantly outpacing the industry average growth rate, showcasing robust global expansion momentum [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Shanghai MicroPort MedBot (Group) Co., Ltd. 上海微創醫療機器人（ 集 團 ）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2252） 截至2025年12月31日止年度 全年業績公告 董事會欣然公佈本集團截至2025年12月31日止年度經審核綜合業績，連同截至 2024年12月31日止年度之比較經審核數據。有關業績已經審計委員會審閱。 本集團於截至2025年12月31日止年度錄得淨虧損人民幣254.1百萬元，而上年 為人民幣647.1百萬元，該變化乃主要由於：(i)營業收入增長和降本增效措施 帶來的毛利增加；(ii)聚焦核心產品研發，提升研發及運營效率帶來的經營費 用下降；(iii)按權益法入賬的海外投資計提的減值撥備減少。 得益於收入增長、戰略聚焦及降本增效措施的成功落實，本集團自由現金流 於2025年下半年實現淨流入。截至2025年1 ...

Core Viewpoint - MicroPort Scientific Corporation (微创机器人-B) is experiencing a significant stock price increase ahead of its earnings announcement, with a rise of 3.64% to HKD 25.06, and a trading volume of HKD 206 million [1] Financial Performance - The company plans to hold a board meeting on March 26 to consider and approve its full-year results for the fiscal year ending December 31, 2025 [1] - Revenue is expected to grow approximately 110% to 120% year-on-year for the fiscal year ending December 31, 2025 [1] - Adjusted net loss is projected to be no more than HKD 240 million, representing a reduction of over 50% compared to the previous year [1] Product and Market Development - The substantial revenue increase is primarily attributed to the breakthrough commercialization of the TiMAY® laparoscopic surgical robot [1] - Sales growth has been particularly strong in overseas markets, with over 100 new orders signed in these regions throughout the year [1] - Overseas market sales revenue is expected to exceed five times that of the previous year [1]